NasdaqGS:WGSHealthcare
GeneDx Fraud Probes And Guidance Cut Put Valuation Gap In Focus
GeneDx Holdings (NasdaqGS:WGS) reported a significant Q1 2026 revenue miss and sharply cut its full year guidance.
Following this update, two law firms launched investigations into potential securities fraud linked to the company’s prior commentary on revenue and profitability.
The investigations focus on whether recent statements were materially misleading, especially given the reaffirmation of optimistic targets shortly before the guidance change.
These events came alongside a steep fall...